SP
SNMMI Podcast Series
SNMMI
Scintillating Conversations: Why Now is the Time to Be in Nuclear Medicine—A Podcast for SNMMI and Nuclear Medicine & Molecular Imaging Professionals
- 22 episodes
- Avg 38 min
- English
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
- SPSeptember 30 · 44 min
How Long is Your Reading List? Brain Imaging in High-Volume Clinics: What we’re seeing, and what’s next.
Your TBR (AKA “to be read”) list may be pretty long if you’re a student, if you’re trying to keep up with the trends on Book Tok, or if you've just made a trip to your favorite local bookstore. Our two guests on this episode of the SNMMI podcasts also have extensive reading lists, but they’re not New York Times best sellers — they’re images of the human brain. Jake Dubroff and Derek Johnson both work in clinics that conduct amyloid and tau PET imaging at high volumes. The scans they’re reading give providers insight into what’s going on in the human brain, particularly when it comes to diagnosing Alzheimer’s and other neurodegenerative diseases. But the use of the scans isn’t nearly as widespread as it could be, mainly due to implementation barriers. Even so, things seem to be changing, especially with the FDA's approval of FET that was only recently announced. To learn more about navigating the work that goes into reading scans, how clinics handle high volumes of patients, and the future role of nuclear medicine in brain imaging, tune into the discussion. Now streaming wherever you listen to podcasts! This episode of the Podcast is sponsored by GE HealthCare. Vizamyl Important Safety Information PRODUCT INDICATIONS AND USE VIZAMYL™(flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease(AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products. CONTRAINDICATIONS VIZAMYL is contraindicated in patients with a history of hypersensitivity reaction to VIZAMYL or polysorbate 80. ADVERSE REACTIONS The most commonly reported adverse reactions in clinical trials were flushing(2%), increased blood pressure(2%), headache nausea and dizziness(1%). Postmarketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Prior to VIZAMYL administration, please read the full Prescribing Information for additional Important Safety Information: https://gehealthcare.com/vizamyl-pi Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPAugust 31 · 22 min
Industry Podcast: Alpha Therapy on the Front Lines
Join moderator Lance Burrell and guests Mike Pintek, President, Nuclear & Precision Health Solutions (NPHS) and Dr. Ramji Rajendran, Radiation Oncologist, UroPartners, LLC, Medical Director of Theranostics and Radiation Oncologist with The Specialty Alliance as they speak about Alpha Therapy. This podcast is sponsored by Cardinal Health, a Value Initiative member. Disclaimer: The clinical views and opinions expressed in this presentation are those of the speakers and are based on their personal clinical experience. It should not be considered medical guidance. Any mention of a specific product is for illustration purposes. Any verbal evaluations and opinions expressed by clinicians are independent and not approved by Cardinal Health. This discussion addresses early-stage research, isotope supply, and operational considerations. Actinium-225-related applications discussed here are investigational unless and until specifically approved in product labeling. No statement should be interpreted as a recommendation regarding safety, effectiveness, patient selection, or standard-of-care use. Health care providers are responsible for all medical decisions regarding the use of any drug products with their patients. Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPJune 15 · 22 min
Industry Podcast: Equal Access, Advanced Imaging: The Role of Mobile PET/CT Today
Join United Imaging, an SNMMI Value Initiative member, for an insightful discussion with moderator Lance Burrell and speakers Jennifer Robinson, Amanda Dieselkamp, and Will Cofer on the evolving role of mobile PET CT in expanding access to advanced molecular imaging. This podcast is brought to you by United Imaging, an SNMMI Value Initiative member. Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPJune 8 · 46 min
So You Want to Be a Medical Physicist...
Was medical physicist an option at your school's career day? If so, lucky you! But if not, you're not alone. It's a pretty niche field, but it has a significant impact on the future of personalized medicine and treating diseases. If you're thinking that this sounds like an intriguing career path, we're joined by physicists working in several different areas of nuclear medicine: quality control, equipment calibration, and research. Ben Auer, PhD, hosts this episode as we learn more about how our guests discovered their career in medical physics, the qualifications needed, and the various opportunities that come with this highly rewarding field. Tune in now! This episode of the Podcast is sponsored by GE HealthCare. Vizamyl Important Safety Information PRODUCT INDICATIONS AND USE VIZAMYL™(flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease(AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products. CONTRAINDICATIONS VIZAMYL is contraindicated in patients with a history of hypersensitivity reaction to VIZAMYL or polysorbate 80. ADVERSE REACTIONS The most commonly reported adverse reactions in clinical trials were flushing(2%), increased blood pressure(2%), headache nausea and dizziness(1%). Postmarketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Prior to VIZAMYL administration, please read the full Prescribing Information for additional Important Safety Information: https://gehealthcare.com/vizamyl-pi Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPApril 6 · 32 min
AI: All Hype, A Source of Hope, or Cause for Hesitation?
This year, 125.6 million people tuned in to watch the Seahawks face the Patriots in the Super Bowl. While the game was the main draw, it's perhaps the one time of year that commercials generate equal excitement. 2026 was no exception, but before the first quarter ended, it was clear which industry dominated the 2026 ad buys: artificial intelligence. AI has become ubiquitous in daily life, and there's almost no industry that hasn't been impacted by its adoption, including nuclear medicine. While some of its applications are clear, questions remain about how AI will be used in clinical settings, patient interactions, image interpretation, and more. On this episode of the SNMMI Podcast, Lance Burrell moderates a discussion with Dmitry Beyer, MPA, CNMT, and Samantha Heasty on AI and its capabilities, potential, and shortcomings. Tune in now! This episode of the SNMMI Podcast is sponsored by GE Healthcare. Important Safety Information – VIZAMYL PRODUCT INDICATIONS AND USE VIZAMYL™ (flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: · Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline · Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products. CONTRAINDICATIONS VIZAMYL is contraindicated in patients with a history of hypersensitivity reaction to VIZAMYL or polysorbate 80. ADVERSE REACTIONS The most commonly reported adverse reactions in clinical trials were flushing (2 %), increased blood pressure (2 %), headache (1 %), nausea and dizziness (1 %). Postmarketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Prior to VIZAMYL administration, please read the full Prescribing Information for additional Important Safety Information: https://gehealthcare.com/vizamyl-pi Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPFebruary 17 · 25 min
The SNMMI Podcast: A Heart-to-Heart on Women’s Cardiac Health
So much of what we know about heart health is based on male models. Classic heart attack symptoms describe the experiences of men, drugs were developed largely by men for men—even in research, mouse models were male. But in recent years, our understanding of women's cardiac health has expanded, and critically, we have learned that we cannot simply apply male models to female patients. As one of our guests says, "women are not small men." For American Heart Month, join us for a heart-to-heart with members of the SNMMI Cardiovascular Council as they discuss how nuclear cardiology is providing new insight into women's heart health. Listen here or wherever you stream your podcasts. This episode of the SNMMI Podcast is sponsored by GE Healthcare. Important Safety Information – VIZAMYL PRODUCT INDICATIONS AND USE VIZAMYL™ (flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: · Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline · Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products. CONTRAINDICATIONS VIZAMYL is contraindicated in patients with a history of hypersensitivity reaction to VIZAMYL or polysorbate 80. ADVERSE REACTIONS The most commonly reported adverse reactions in clinical trials were flushing (2 %), increased blood pressure (2 %), headache (1 %), nausea and dizziness (1 %). Postmarketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Prior to VIZAMYL administration, please read the full Prescribing Information for additional Important Safety Information: https://gehealthcare.com/vizamyl-pi Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPDec 15, 2025 · 24 min
Neurology and Nuclear Medicine
Join Phillip Kuo, MD, PhD, and Jacob Dubroff, MD, PhD as they delve into discussions about the latest tracers, brain imaging techniques, and advances in patient care. To learn more about advancements in neurology in nuclear medicine, register for the upcoming SNMMI Mid-Winter Meeting with a dedicated neurology track. Register Here: https://snmmi.org/MWM/MWM/Attend/Register.aspx Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPS2 · E6Dec 4, 2025 · 51 min
Part 2 of 2: Nuclear Medicine Physicians for the Future – Closing the Early Exposure Gap
Join Lance Burrell for a continued conversation on nuclear medicine physicians of the future with Munir Ghesani, MD and Jean-Luc Urbain, MD, PhD. Together, they cover the medical student curriculum, current programs available, and the future of nuclear medicine. Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPOct 14, 2025 · 32 min
The Science of Seeing: Nuclear Imaging in Breast Cancer Care
Join Lance Burrell for an insightful conversation with Dr. Gary Ulaner, as they discuss the role of nuclear medicine in breast cancer treatment and lesser-known breast cancer types. Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPS2 · E4Aug 4, 2025 · 30 min
Part 1 of 2: Nuclear Medicine Physicians for the Future – Physician-in-Training Perspective
Join Dr. Faraz Farhadi and Dr. Navid Hasani as they discuss solutions to recruiting nuclear medicine physicians and expanding the pipeline of trainees. Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPJul 31, 2025 · 26 min
Industry Podcast: A New Era in Alzheimer's Diagnostics
This podcast is brought to you by Lilly, member of the SNMMI Value Initiative Industry Alliance. Hosts Anupa Arora, MD and Anthony “Nino” Sireci, MD discuss a New Era in Alzheimer Diagnostics. This episode takes a focused look at high-impact topics shaping the future of Nuclear Medicine and Molecular Imaging, designed specifically for professionals driving value in the field. Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPS2 · E3Jun 2, 2025 · 45 min
Shining a Light on Dementia: The Progress of Nuclear Medicine
June is Alzheimer's and Brain Awareness month, join Phillip Kuo, MD, PhD as he delves into the history of neurodegenerative disorders and the progress nuclear medicine has made to help diagnose and treat diseases like dementia and Alzheimer’s. Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPS2 · E2Apr 1, 2025 · 18 min
RPT Centers of Excellence - Trends, Insights, and Impacts
Join Bonnie Clarke, Senior Director of Research and Development at SNMMI, and Richard Wahl, MD, Mallinckrodt Institute of Radiology Professor, past president of SNMMI, and founder of the Mars Shot, as they talk about the Radiopharmaceutical Therapy Centers of Excellence (RPTCOE) program and see how nuclear medicine plays a key role in patient care. Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SP
S2 · E1Feb 26, 2025 · 30 minAmerican Heart Month and The Vital Role of Nuclear Cardiology
In this special American Heart Month episode, Lance Burrell—nuclear medicine technologist and SNMMI Research and Discovery imaging specialist—sits down with Dr. Richard Weinberg, MD, PhD, the Medical Director of Nuclear Cardiology at Northwestern’s Bluhm Cardiovascular Institute and President of the SNMMI Cardiovascular Council. Dr. Weinberg shares expert insights on the critical role of nuclear medicine in heart health, the latest advancements in nuclear cardiology, and the power of prevention in cardiovascular care. Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPS1 · E13Dec 17, 2024 · 1 hr 23 min
Industry Podcast: AI's Promise in Nuclear Medicine
This podcast is brought to you by GE HealthCare, an SNMMI Value Initiative member. This podcast asks about AI's promise in nuclear medicine in image acquisition, image reconstruction, post processing, computer diagnosis has been promising, but clinical adoption will require AI to provide a higher value compared to the standard of care. This podcast will ask question such as how can AI provide this improved bio nuclear medicine? What are some of the strategies that can help us with AI demonstrating clinical value? What are some of the initiatives that we can take as a society and as a community to strengthen this value, and how can we rally the community to take steps towards strengthening this value? Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPS1 · E12Oct 22, 2024 · 1 hr 4 min
Industry Podcast: New Frontiers in Artificial Intelligence
This podcast is brought to you by GE HealthCare, an SNMMI Value Initiative member. Hosts Zhiyong Lu, PhD and Jong Chul Ye, PhD speak about emerging territories in the broadening domain of Artificial Intelligence and learning about generative AI. Dr. Lu will speak the work he has done in AI in the context national language processing. Dr. Ye will speak on generative AI in imaging. Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPS1 · E11Sep 12, 2024 · 37 min
Industry Podcast: CMIT- Center for Molecular Imaging and Therapy
This podcast is brought to you by United Imaging, co-chair of the SNMMI Value Initiative Industry Alliance. Hosts Munir Ghesani, MD, former President of SNMMI, co-chair of the Mars Shot Research Fund, and Stephen Lokitz, MD, a Nuclear Medicine physicist and Executive Director and Director of Imaging Sciences at the Center for Molecular Imaging and Therapy, or CMIT, discuss nuclear medicine procedures performed and their plans for the future. Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPS1 · E10Jul 29, 2024 · 30 min
Mathematical Oncology & Radiopharmaceutical Therapy
This episode is a recorded presentation delivered by Robert Gatenby, MD from the Moffitt Cancer Center during the opening plenary at the SNMMI 2024 Artificial Intelligence Summit, "AI In Action" held Feb 29 - March 1, 2024. Dr. Gatenby has used evolutionary dynamics models to develop an adaptive therapy approach for the treatment of cancer which he describes during his talk. Join this podcast and discover an innovative and effective approach to treating cancer – the use of evolutionary biology, mathematical oncology and radiopharmaceutical therapy. Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X
- SPS1 · E9Mar 19, 2024 · 46 min
The Latest in the Clinical Use of Amyloid and Tau Imaging
Drs. Jon McConathy, David A. Wolk, and Illya M. Nasrallah provide an update and information about neuro imaging related to Alzheimer's disease, particularly amyloid and tau imaging. Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X